Q1 2025 EPS Estimates for Sarepta Therapeutics, Inc. Increased by Zacks Research (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Investment analysts at Zacks Research boosted their Q1 2025 earnings estimates for Sarepta Therapeutics in a research note issued on Tuesday, September 17th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings per share of $2.04 for the quarter, up from their prior estimate of $1.78. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $1.47 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ Q2 2025 earnings at $2.35 EPS, Q3 2025 earnings at $2.30 EPS, Q4 2025 earnings at $2.36 EPS and FY2025 earnings at $9.05 EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.06. The firm had revenue of $362.90 million during the quarter, compared to analysts’ expectations of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.27) earnings per share.

Other analysts have also recently issued research reports about the stock. Royal Bank of Canada restated an “outperform” rating and set a $181.00 target price on shares of Sarepta Therapeutics in a research note on Thursday. BMO Capital Markets raised their price target on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a research report on Monday, June 24th. UBS Group raised their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the stock a “buy” rating in a research report on Tuesday. Bank of America raised their price target on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a “buy” rating in a research report on Friday, June 21st. Finally, William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Three analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $187.39.

Sarepta Therapeutics Stock Performance

NASDAQ SRPT opened at $127.21 on Thursday. The firm has a 50-day moving average of $137.76 and a 200-day moving average of $132.57. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90. The stock has a market cap of $12.02 billion, a PE ratio of 1,145.09 and a beta of 0.81. Sarepta Therapeutics has a 52-week low of $55.25 and a 52-week high of $173.25.

Institutional Investors Weigh In On Sarepta Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Sarepta Therapeutics by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock worth $850,139,000 after buying an additional 243,180 shares during the period. Capital International Investors boosted its position in Sarepta Therapeutics by 1.6% during the 1st quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock worth $623,676,000 after buying an additional 76,032 shares during the period. Avoro Capital Advisors LLC boosted its position in Sarepta Therapeutics by 7.9% during the 4th quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after buying an additional 319,444 shares during the period. Wellington Management Group LLP lifted its position in shares of Sarepta Therapeutics by 5.6% in the 4th quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock worth $398,025,000 after purchasing an additional 217,810 shares during the period. Finally, Farallon Capital Management LLC lifted its position in shares of Sarepta Therapeutics by 102.8% in the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after purchasing an additional 1,243,427 shares during the period. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Sarepta Therapeutics

In related news, insider Bilal Arif sold 7,859 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the sale, the insider now directly owns 21,261 shares of the company’s stock, valued at approximately $3,467,243.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Bilal Arif sold 7,859 shares of Sarepta Therapeutics stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the sale, the insider now owns 21,261 shares in the company, valued at $3,467,243.88. The disclosure for this sale can be found here. In the last three months, insiders have sold 52,801 shares of company stock valued at $8,399,586. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.